CD4 and pneumocystosis: Given the low overall risk of PCP with CD4 count between 101–200 cells/μL, combined with the drawbacks of prophylaxis for OIs, we suggest a revision of clinical guidelines for primary prophylaxis is merited to include consideration of the VL.